Next Article in Journal
In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients
Next Article in Special Issue
Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management
Previous Article in Journal
Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
Open AccessReview

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview

1
Medical Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II” of Bari, Viale Orazio Flacco, 65, 70124 Bari, Italy
2
Department of Biomedical Sciences and Human Oncology, University of Bari “Ando Moro”, Piazza Giulio Cesare, 11, 70124 Bari, Italy
3
Department of Radiology, IRCCS Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco, 65, 70124 Bari, Italy
4
Medical Oncology, Campus Bio-Medico University of Rome, Álvaro del Portillo, 21, 00128 Rome, Italy
*
Author to whom correspondence should be addressed.
These Authors equally contributed to this work.
These Authors equally conceptualized this manuscript.
Cancers 2019, 11(9), 1270; https://doi.org/10.3390/cancers11091270
Received: 5 August 2019 / Revised: 16 August 2019 / Accepted: 27 August 2019 / Published: 29 August 2019
(This article belongs to the Special Issue Targeting Bone Metastasis in Cancers)
Skeletal metastases of unknown primary (SMUP) represent a clinical challenge in dealing with patients diagnosed with bone metastases. Management of these patients has improved significantly in the past few years. however, it is fraught with a lack of evidence. While some patients have achieved impressive gains, a more systematic and tailored treatment is required. Nevertheless, in real-life practice, the outlook at the beginning of treatment for SMUP is decidedly somber. An incomplete translational relevance of pathological and clinical data on the mortality and morbidity rate has had unsatisfactory consequences for SMUP patients and their physicians. We examined several approaches to confront the available evidence; three key points emerged. The characterization of the SMUP biological profile is essential to driving clinical decisions by integrating genetic and molecular profiles into a multi-step diagnostic work-up. Nonetheless, a pragmatic investigation plan and therapy of SMUP cannot follow a single template; it must be adapted to different pathophysiological dynamics and coordinated with efforts of a systematic algorithm and high-quality data derived from statistically powered clinical trials. The discussion in this review points out that greater efforts are required to face the unmet needs present in SMUP patients in oncology. View Full-Text
Keywords: skeletal metastases of unknown primary; SMUP; bone metastases; unknown primary tumor; bisphosphonates; bone markers; tumor microenvironment skeletal metastases of unknown primary; SMUP; bone metastases; unknown primary tumor; bisphosphonates; bone markers; tumor microenvironment
Show Figures

Figure 1

MDPI and ACS Style

Argentiero, A.; Solimando, A.G.; Brunetti, O.; Calabrese, A.; Pantano, F.; Iuliani, M.; Santini, D.; Silvestris, N.; Vacca, A. Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. Cancers 2019, 11, 1270.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop